Supreme Court of Victoria, VIC.
Med J Aust. 2010 Jul 5;193(1):26-9. doi: 10.5694/j.1326-5377.2010.tb03736.x.
Mifepristone is a safe, effective and relatively cheap drug that plays an important role in women's health care and is widely used for early medical abortion in many countries. The Therapeutic Goods Administration (TGA) can authorise mifepristone to be imported into and marketed in Australia. To date, no pharmaceutical company has applied to register mifepristone in Australia. The TGA can also permit medical practitioners to prescribe medicine that is not approved for marketing in Australia under the Authorised Prescribers scheme. The number of approvals for mifepristone has gradually increased, in spite of a complicated and protracted application process. Approval under the Authorised Prescribers scheme requires medical practitioners to comply with state or territory legislation. Abortion laws in Australia vary between jurisdictions, and in some states the law is unclear and confusing. The decriminalisation of abortion in all Australian jurisdictions would protect medical practitioners from criminal liability, promote the health interests of Australian women, and discourage the illegal importation of abortifacients that are being used without quality controls or medical supervision. The Victorian Abortion Law Reform Act 2008 is one legislative model for this.
米非司酮是一种安全、有效且相对廉价的药物,在女性保健中发挥着重要作用,在许多国家被广泛用于早期药物流产。治疗商品管理局(TGA)可以授权将米非司酮进口到澳大利亚并在澳大利亚销售。迄今为止,没有制药公司在澳大利亚申请注册米非司酮。TGA 还可以允许医生根据授权处方医生计划开具有未在澳大利亚获得批准上市的药物。尽管申请过程复杂而漫长,但米非司酮的批准数量逐渐增加。根据授权处方医生计划获得批准,医生需要遵守州或地区立法。澳大利亚的堕胎法在司法管辖区之间有所不同,在一些州,法律不明确且令人困惑。在所有澳大利亚司法管辖区使堕胎合法化将使医生免受刑事责任,促进澳大利亚妇女的健康利益,并阻止未经质量控制或医疗监督使用的堕胎药的非法进口。2008 年维多利亚堕胎法改革法案就是这样的一个立法模式。